Gufic Biosciences Limited is happy to announce that it has entered into a research and cooperation agreement with Selvax Pty Ltd, a biotechnology company located in Perth, Western Australia, to help Selvax commercialise their cancer immunotherapy treatment.
The deal’s exclusive financial adviser is Orbit Financial Capital, a boutique investment banking business with a solid footing in corporate finance, transaction advisory services, and loan syndication services.
Gufic will undertake mutually agreed development activities in exchange for exclusive commercial rights to Selvax immunotherapy in India, as well as an equal share of future revenues derived from future sales of the product in Europe, subject to regulatory approvals in India and Europe.
